First CAR T Therapy for Relapsed or Refractory Adult ALL Now Reimbursed in Ireland
Gilead Sciences and Kite have confirmed that Tecartus (brexucabtagene autoleucel), the first CAR T therapy for relapsed or refractory adult B-cell precursor acute lymphoblastic leukaemia, is now reimbursed in Ireland, offering a personalised treatment option supported by pivotal ZUMA-3 trial data.
Read more